Liver Cancer/HCC
Liver Cancer/HCC
AASLD 2017: Nivolumab Improves Outcomes in Liver Cancer Study
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
Nivolumab (Opdivo), a PD-1 checkpoint inhibitor that helps the immune system fight cancer, was associated with a decrease in tumor size or disease stabilization in patients with hepatocellular carcinoma (HCC) in the CheckMate 040 study, according to a report at the 2017 AASLD Liver Meeting last month in Washington, DC.
Coverage of the 2017 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Washington, DC, October 20-24, 2017.
Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.
Full coverage listing by topic
11/30/17
FDA Approves Nivolumab Immunotherapy for Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 12 October 2017 00:00
- Written by Liz Highleyman
In September, the U.S. Food and Drug Administration granted accelerated approval for nivolumab (Opdivo), an immunotherapy drug that restores T-cell anti-tumor activity, for people with hepatocellular carcinoma (HCC).
AASLD 2017: Curing Hepatitis C with DAAs Reduces Liver Cancer Risk
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 31 October 2017 00:00
- Written by Liz Highleyman
People who achieved a sustained virological response to hepatitis C treatment lowered their risk of hepatocellular carcinoma by around 70%, regardless of whether they were treated with new direct-acting antivirals (DAAs) or older interferon-based therapy, according to study results presented at the 2017 AASLD Liver Meeting last week in Washington, DC.
FDA Approves Nivolumab Immunotherapy for Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 12 October 2017 00:00
- Written by Liz Highleyman
In September, the U.S. Food and Drug Administrationgranted accelerated approval for nivolumab (Opdivo), an immunotherapy drug that restores T-cell anti-tumor activity, for people with hepatocellular carcinoma (HCC).
More Articles...
- EASL 2017: Generic Hepatitis C Drugs Continue to Produce High Cure Rates
- EASL 2017: Hepatitis C Treatment Allows 1 in 4 to Come Off Liver Transplant Waiting List
- EASL 2017: EASL Releases Updated Hepatitis B Guidelines at International Liver Congress
- EASL 2017: Switching to TAF for Hepatitis B Improves Kidney Function and Bone Loss
Web Design and Development by